Brief: Cantargia Presents Positive Phase Ib Data In Breast Cancer Drug Study

Cantargia AB

23/10/2023 09:32

Oct 23 (Reuters) - Cantargia AB  CANTA.ST :
    * SAID ON SATURDAY PRESENTED POSITIVE EFFICACY SIGNALS AND
FAVORABLE SAFETY FROM PHASE IB OF CLINICAL TRIAL TRIFOUR
INVESTIGATING THE IL1RAP-BINDING ANTIBODY NADUNOLIMAB IN
METASTATIC TRIPLE-NEGATIVE BREAST CANCER
    * COMBINATION WAS WELL TOLERATED WITH SAFETY PROFILE SIMILAR
TO
CHEMOTHERAPY ONLY
    * NADUNOLIMAB COMBINED WITH CHEMOTHERAPY SHOWED RESPONSE
RATE OF
60% AND MEDIAN PFS OF 6.6 MONTHS IN 15 PATIENTS, WELL ABOVE
HISTORICAL CONTROL DATA

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN9KS8VW
 Further company coverage:  CANTA.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))